Congestive Heart Failure News and Research RSS Feed - Congestive Heart Failure News and Research

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
New predictive analytics model identifies congestive heart failure patients with high readmission risk

New predictive analytics model identifies congestive heart failure patients with high readmission risk

Readmission of patients with chronic diseases is a growing problem, costing the U.S. health care system about $25 billion each year. Researchers at The University of Texas at Dallas developed a predictive analytics model that can identify congestive heart failure patients with high readmission risk and potentially help stymie those costs. [More]
Kaiser Permanente, Intermountain Healthcare to participate in U.S. News Hospital Outcome Data Disclosure Program

Kaiser Permanente, Intermountain Healthcare to participate in U.S. News Hospital Outcome Data Disclosure Program

U.S. News & World Report, publisher of Best Hospitals and Best Children's Hospitals, today announced that Kaiser Permanente and Intermountain Healthcare will participate in the U.S. News Hospital Outcome Data Disclosure Program, a new data-collection initiative designed to evaluate hospitals more completely and give patients better information about the hospitals in their communities. [More]
Intervention to connect low-income uninsured patients to primary care could improve health, reduce costs

Intervention to connect low-income uninsured patients to primary care could improve health, reduce costs

An intervention to connect low-income uninsured and Medicaid patients to a reliable source of primary health care shows promise for reducing avoidable use of hospital emergency departments in Maryland. A University of Maryland School of Public Health study evaluating the results of the intervention was published this week in the May issue of the journal Health Affairs. [More]
Global market for cardiac rhythm management devices worth $13 billion for 2015

Global market for cardiac rhythm management devices worth $13 billion for 2015

The global market for cardiac rhythm management devices such as pacemakers and defibrillators is worth about $13 billion for 2015, according to Kalorama Information. The market research publisher said the market has benefited from the demand to move to a more mobile, wireless and efficient system both within major health facilities and in the home treatment markets. There is also an increasing trend to upgrade to more portable devices and devices which have added benefits such as MRI compatibility. [More]
MGH researchers find probable mechanism associated with risk of developing serious diseases

MGH researchers find probable mechanism associated with risk of developing serious diseases

Massachusetts General Hospital investigators have found the probable mechanism underlying a previously described biomarker associated with the risk of developing serious diseases ranging from cancer to cardiovascular disease and the risk of serious complications. In a paper published in the American Journal of Hematology, the research team reports finding that higher levels of a measure routinely taken as part of the complete blood count - the extent of variation in the size of red blood cells - is caused by reduced clearance of aging cells from the bloodstream. [More]
Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai, Arena complete two Phase 1 registrational trials for once-daily formulation of lorcaserin

Eisai Inc. and Arena Pharmaceuticals, Inc. today announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as compared to the twice-daily immediate release formulation approved by the US Food and Drug Administration and marketed as BELVIQ. [More]

Cardio3 BioSciences announces successful completion of futility analysis for C-Cure

Cardio3 BioSciences, a leader in engineered cell therapy treatments, today announced the successful completion of a futility analysis for C-Cure, its lead cell therapy for congestive heart failure, currently being evaluated in a Phase III clinical trial in Europe and Israel (CHART-1). [More]
Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira announces availability of INFLECTRA (infliximab) in Canada

Hospira, Inc., a global leader in biosimilars and the world's leading provider of injectable drugs and infusion technologies, announces the availability of INFLECTRA (infliximab) in Canada, the country's first subsequent entry biologic (SEB) monoclonal antibody (mAb) therapy. [More]
Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen receives FDA priority review designation for Kyprolis to treat relapsed multiple myeloma

Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy. [More]
Penn surgeons develop new tools to identify joint replacement patients at risk for serious complications

Penn surgeons develop new tools to identify joint replacement patients at risk for serious complications

Orthopedic surgeons from the Perelman School of Medicine at the University of Pennsylvania have developed two new prediction tools aimed at identifying total hip and knee replacement patients who are at-risk of developing serious complications after surgery. [More]
C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

C3BS plans to open new U.S.-based facility to manufacture C-Cure for use in Phase III trial

Cardio3 BioSciences, a leader in the discovery and development of engineered cell therapies, today confirmed plans to open a new U.S.-based manufacturing facility in Rochester, Minnesota. The facility will support the Company’s current and anticipated manufacturing needs in the United States for both the Phase III clinical trial evaluating lead cardiovascular product candidate C-Cure (CHART-2), and its recently acquired CAR T-cell therapies’ portfolio. [More]
New drug fails to prevent irreversible injury to the heart after angioplasty

New drug fails to prevent irreversible injury to the heart after angioplasty

Patients who received the new drug Bendavia before undergoing angioplasty or receiving a stent to clear blocked arteries after a heart attack showed no significant reduction in scarring as compared to patients given a placebo, according to a study presented at the American College of Cardiology's 64th Annual Scientific Session. [More]
Endovascular aneurysm repair procedure can extend lives even in high-risk patients: Study

Endovascular aneurysm repair procedure can extend lives even in high-risk patients: Study

Minimally invasive surgery can prevent a fatal rupture of an abdominal aortic aneurysm. [More]
Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo announces commercial availability of NATESTO nasal gel for men with hypogonadism

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (TSX: ENL), announced today the commercial availability of NATESTO (testosterone nasal gel), the first and only nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism. [More]
Ablative Solutions named recipient of CRT's Top Cardiovascular Innovation Award

Ablative Solutions named recipient of CRT's Top Cardiovascular Innovation Award

Ablative Solutions, Inc., a venture-backed, privately-held clinical stage company headquartered in Kalamazoo, MI, with offices in Menlo Park, CA, announced today that it was the recipient of a "Top Cardiovascular Innovation Award" from Cardiovascular Research Technologies for the Peregrine System. [More]
Common antidepressant medications not helpful for people with mood, anxiety disorders

Common antidepressant medications not helpful for people with mood, anxiety disorders

Studies indicate that the majority of people with mood and anxiety disorders who receive the most commonly prescribed class of antidepressant medications, Selective Serotonin Reuptake Inhibitors or SSRI's, are not helped by these medications. SSRIs are designed to increase serotonin, a neurotransmitter in the brain that is key to maintenance of mood. [More]
New guidelines advise nearly all women, people with AFib to take blood thinners

New guidelines advise nearly all women, people with AFib to take blood thinners

Nearly all women and people over 65 in the U.S. with atrial fibrillation are advised to take blood thinners under new guidelines based on an analysis from the Duke Clinical Research Institute. [More]
Vectorious Medical Technologies closes $5 million financing round

Vectorious Medical Technologies closes $5 million financing round

Vectorious Medical Technologies, an Israeli company developing a novel cardiac monitoring system for patients suffering from congestive heart failure (CHF), announced today that it has closed a $5 million financing round. [More]
Novartis’ heart failure medicine LCZ696 granted FDA priority review

Novartis’ heart failure medicine LCZ696 granted FDA priority review

LCZ696, a twice-a-day medicine being investigated for heart failure, acts to enhance the protective neurohormonal systems of the heart (NP system) while simultaneously suppressing the harmful effects of the overactive renin-angiotensin-aldosterone system (RAAS). [More]
Advertisement